Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.87 CAD | +0.52% | -6.52% | -2.03% |
05-09 | Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.03% | 89.59M | |
+20.86% | 72.45B | |
-4.67% | 23.46B | |
+4.89% | 8.59B | |
+7.11% | 8.35B | |
-23.73% | 7.88B | |
+13.92% | 5.21B | |
-0.59% | 4.11B | |
+7.85% | 4.09B | |
+20.65% | 3.6B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Brief: Updates Its Peak-year Sales Estimate to $250-300 Million in Revenue with Adjusted EBITDA Margin of Near 30%